MetaVia Inc.
MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed… Read more
MetaVia Inc. (MTVA) - Total Liabilities
Latest total liabilities as of September 2025: $8.43 Million USD
Based on the latest financial reports, MetaVia Inc. (MTVA) has total liabilities worth $8.43 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
MetaVia Inc. - Total Liabilities Trend (2014–2024)
This chart illustrates how MetaVia Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
MetaVia Inc. Competitors by Total Liabilities
The table below lists competitors of MetaVia Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
CTT Pharmaceutical Holdings Inc
PINK:CTTH
|
USA | $20.03K |
|
INSMED
BE:IM8N
|
Germany | €1.57 Billion |
|
ATI Physical Therapy Inc
NYSE:ATIP
|
USA | $1.13 Billion |
|
EQUIFAX INC - Dusseldorf Stock Exchang
DU:EFX
|
Germany | €7.30 Billion |
|
Lord Resources Ltd
AU:LRD
|
Australia | AU$361.05K |
|
Oscar Properties Holding AB
ST:OP
|
Sweden | Skr2.37 Billion |
|
Forbidden Foods Ltd
AU:FFF
|
Australia | AU$1.89 Million |
|
Kancera AB (publ)
ST:KAN
|
Sweden | Skr3.58 Million |
Liability Composition Analysis (2014–2024)
This chart breaks down MetaVia Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.74 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.33 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.57 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how MetaVia Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for MetaVia Inc. (2014–2024)
The table below shows the annual total liabilities of MetaVia Inc. from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $8.33 Million | +36.63% |
| 2023-12-31 | $6.10 Million | -48.27% |
| 2022-12-31 | $11.78 Million | +435.15% |
| 2021-12-31 | $2.20 Million | -41.51% |
| 2020-12-31 | $3.77 Million | +73.02% |
| 2019-12-31 | $2.18 Million | -87.28% |
| 2018-12-31 | $17.11 Million | +13.47% |
| 2017-12-31 | $15.08 Million | +265.74% |
| 2016-12-31 | $4.12 Million | -75.57% |
| 2015-12-31 | $16.87 Million | +1819.23% |
| 2014-12-31 | $879.00K | -- |